Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

Clinical trial NCT04615143 · RECRUITING

Trial details

NCT number: NCT04615143
Sponsor: Sun Yat-sen University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Hepatocellular Carcinoma

Start date: 2020-12-01
Primary completion: 2026-12-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.